150 related articles for article (PubMed ID: 36193598)
1. Solid phase radiosynthesis of an olaparib derivative using 4-[
Xu J; Chen H; Rogers BE; Katzenellenbogen JA; Zhou D
Nucl Med Biol; 2022; 114-115():65-70. PubMed ID: 36193598
[TBL] [Abstract][Full Text] [Related]
2. Preliminary evaluation of a novel
Zhou D; Xu J; Mpoy C; Chu W; Kim SH; Li H; Rogers BE; Katzenellenbogen JA
Nucl Med Biol; 2018 Nov; 66():26-31. PubMed ID: 30195072
[TBL] [Abstract][Full Text] [Related]
3. Positron-Emission Tomographic Imaging of a Fluorine 18-Radiolabeled Poly(ADP-Ribose) Polymerase 1 Inhibitor Monitors the Therapeutic Efficacy of Talazoparib in SCLC Patient-Derived Xenografts.
Laird J; Lok BH; Carney B; Kossatz S; de Stanchina E; Reiner T; Poirier JT; Rudin CM
J Thorac Oncol; 2019 Oct; 14(10):1743-1752. PubMed ID: 31195178
[TBL] [Abstract][Full Text] [Related]
4. A one-pot radiosynthesis of [
Wilson TC; Pillarsetty N; Reiner T
J Labelled Comp Radiopharm; 2020 Jul; 63(9):419-425. PubMed ID: 32391930
[TBL] [Abstract][Full Text] [Related]
5. Fluorine-18 labeled poly (ADP-ribose) polymerase1 inhibitor as a potential alternative to 2-deoxy-2-[
Demétrio de Souza França P; Roberts S; Kossatz S; Guru N; Mason C; Zanoni DK; Abrahão M; Schöder H; Ganly I; Patel SG; Reiner T
Nucl Med Biol; 2020; 84-85():80-87. PubMed ID: 32135475
[TBL] [Abstract][Full Text] [Related]
6. Radiosynthesis and Evaluation of Talazoparib and Its Derivatives as PARP-1-Targeting Agents.
Zhou D; Chen H; Mpoy C; Afrin S; Rogers BE; Garbow JR; Katzenellenbogen JA; Xu J
Biomedicines; 2021 May; 9(5):. PubMed ID: 34069967
[TBL] [Abstract][Full Text] [Related]
7. In vivo visualization of PARP inhibitor pharmacodynamics.
McDonald ES; Pantel AR; Shah PD; Farwell MD; Clark AS; Doot RK; Pryma DA; Carlin SD
JCI Insight; 2021 Apr; 6(8):. PubMed ID: 33884961
[TBL] [Abstract][Full Text] [Related]
8. PARP-1 activity (PAR) determines the sensitivity of cervical cancer to olaparib.
Bianchi A; Lopez S; Altwerger G; Bellone S; Bonazzoli E; Zammataro L; Manzano A; Manara P; Perrone E; Zeybek B; Han C; Menderes G; Ratner E; Silasi DA; Huang GS; Azodi M; Newberg JY; Pavlick DC; Elvin J; Frampton GM; Schwartz PE; Santin AD
Gynecol Oncol; 2019 Oct; 155(1):144-150. PubMed ID: 31434613
[TBL] [Abstract][Full Text] [Related]
9. Design, Synthesis, and Evaluation of [
Zheng W; Huang Y; Xie Y; Yang T; Cheng X; Chen H; Li C; Jiang Z; Yu Z; Li Z; Zhang L; Yuan L; Liu Y; Liang Y; Wu Z
Mol Pharm; 2024 May; 21(5):2606-2621. PubMed ID: 38606716
[TBL] [Abstract][Full Text] [Related]
10. Manual and automated Cu-mediated radiosynthesis of the PARP inhibitor [
Guibbal F; Isenegger PG; Wilson TC; Pacelli A; Mahaut D; Sap JBI; Taylor NJ; Verhoog S; Preshlock S; Hueting R; Cornelissen B; Gouverneur V
Nat Protoc; 2020 Apr; 15(4):1525-1541. PubMed ID: 32111986
[TBL] [Abstract][Full Text] [Related]
11. Synthesis, [¹⁸F] radiolabeling, and evaluation of poly (ADP-ribose) polymerase-1 (PARP-1) inhibitors for in vivo imaging of PARP-1 using positron emission tomography.
Zhou D; Chu W; Xu J; Jones LA; Peng X; Li S; Chen DL; Mach RH
Bioorg Med Chem; 2014 Mar; 22(5):1700-7. PubMed ID: 24503274
[TBL] [Abstract][Full Text] [Related]
12. Activation of Wnt signaling promotes olaparib resistant ovarian cancer.
Yamamoto TM; McMellen A; Watson ZL; Aguilera J; Ferguson R; Nurmemmedov E; Thakar T; Moldovan GL; Kim H; Cittelly DM; Joglar AM; Brennecke EP; Wilson H; Behbakht K; Sikora MJ; Bitler BG
Mol Carcinog; 2019 Oct; 58(10):1770-1782. PubMed ID: 31219654
[TBL] [Abstract][Full Text] [Related]
13. Initial evaluation of Cu-64 labeled PARPi-DOTA PET imaging in mice with mesothelioma.
Huang T; Hu P; Banizs AB; He J
Bioorg Med Chem Lett; 2017 Aug; 27(15):3472-3476. PubMed ID: 28587822
[TBL] [Abstract][Full Text] [Related]
14. Two experts and a newbie: [
Stotz S; Kinzler J; Nies AT; Schwab M; Maurer A
Eur J Nucl Med Mol Imaging; 2022 Feb; 49(3):834-846. PubMed ID: 34486071
[TBL] [Abstract][Full Text] [Related]
15. Poly (ADP-ribose) polymerase (PARP) inhibitor regimens for ovarian cancer in phase III randomized controlled trials: a network meta-analysis.
Gong H; Nie D; Huang Y; Li Z
Int J Gynecol Cancer; 2020 Oct; 30(10):1576-1582. PubMed ID: 32817083
[TBL] [Abstract][Full Text] [Related]
16. Enhancement of Soft Tissue Sarcoma Cell Radiosensitivity by Poly(ADP-ribose) Polymerase-1 Inhibitors.
Mangoni M; Sottili M; Salvatore G; Meattini I; Desideri I; Greto D; Loi M; Becherini C; Garlatti P; Delli Paoli C; Dominici L; Gerini C; Scoccianti S; Bonomo P; Silvano A; Beltrami G; Campanacci D; Livi L
Radiat Res; 2018 Nov; 190(5):464-472. PubMed ID: 30067444
[TBL] [Abstract][Full Text] [Related]
17. PET Imaging of PARP Expression Using
Wilson TC; Xavier MA; Knight J; Verhoog S; Torres JB; Mosley M; Hopkins SL; Wallington S; Allen PD; Kersemans V; Hueting R; Smart S; Gouverneur V; Cornelissen B
J Nucl Med; 2019 Apr; 60(4):504-510. PubMed ID: 30389822
[TBL] [Abstract][Full Text] [Related]
18. The Development of
Lee HS; Schwarz SW; Schubert EK; Chen DL; Doot RK; Makvandi M; Lin LL; McDonald ES; Mankoff DA; Mach RH
Radiol Imaging Cancer; 2022 Jan; 4(1):e210070. PubMed ID: 35089089
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and radiopharmacological evaluation of a high-affinity and metabolically stabilized 18F-labeled bombesin analogue for molecular imaging of gastrin-releasing peptide receptor-expressing prostate cancer.
Richter S; Wuest M; Krieger SS; Rogers BE; Friebe M; Bergmann R; Wuest F
Nucl Med Biol; 2013 Nov; 40(8):1025-34. PubMed ID: 23969085
[TBL] [Abstract][Full Text] [Related]
20. Pilot Study: PARP1 Imaging in Advanced Prostate Cancer.
Dehdashti F; Reimers MA; Shoghi KI; Chen DL; Luo J; Rogers B; Pachynski RK; Sreekumar S; Weimholt C; Zhou D
Mol Imaging Biol; 2022 Dec; 24(6):853-861. PubMed ID: 35701722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
